Watson, Nathaniel F.
Davis, Craig W.
Zarycranski, Donna
Vaughn, Ben
Dayno, Jeffrey M.
Dauvilliers, Yves
Schwartz, Jean-Charles
Clinical trials referenced in this document:
Documents that mention this clinical trial
Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials
https://doi.org/10.1007/s40263-021-00886-x
Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials
https://doi.org/10.1007/s40263-021-00866-1
Documents that mention this clinical trial
Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials
https://doi.org/10.1007/s40263-021-00886-x
Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials
https://doi.org/10.1007/s40263-021-00866-1
Funding for this research was provided by:
Bioprojet Pharma (Studies)
Harmony Biosciences LLC (Technical editorial and medical writing assistance support)
Article History
Accepted: 26 September 2021
First Online: 25 November 2021
Declarations
:
: The studies from which the data analyzed in this paper were derived (NCT 1067222 and NCT 01800045) were funded by Bioprojet Pharma, Paris, France; the analysis reported in this paper and open access were funded by Harmony Biosciences LLC, Plymouth Meeting, PA, USA.
: NFW reports serving as a consultant for Harmony Biosciences, LLC, Jazz Pharmaceuticals, and SleepScore Labs. CWD, DZ, and JMD are employees of Harmony Biosciences, LLC. BV is an employee of Rho. YD reports receiving funds for speaking, board engagements, and travel to conferences from Avadel/Flamel, Bioprojet Pharma, Harmony Biosciences, LLC, Idorsia, Jazz Pharmaceuticals, Takeda, Theranexus, and UCB Pharma. JCS is a co-founder of Bioprojet Pharma.
: Both studies (NCT 1067222 and NCT 01800045) were conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonisation and the ethical principles of the Declaration of Helsinki. Each study protocol was approved by an institutional review board or independent ethics committee at each study site.
: All patients provided written informed consent before study enrollment.
: Not applicable.
: The datasets generated and/or analyzed for the current study are not publicly available.
: Not applicable.
: NFW: data analysis and interpretation, and review and editing of the article; CWD: conceptualization, data analysis and interpretation, and review and editing of the article; DZ: conceptualization, data analysis and interpretation, and review and editing of the article; BV: data analysis, and review and editing of the article; JMD: conceptualization, data analysis and interpretation, and review and editing of the article; YD: data analysis and interpretation, and review and editing of the article; and JCS: conceptualization, data analysis and interpretation, and review and editing of the article. All authors provided input into the drafting of the manuscript, have reviewed and approved the final version, and agree to be accountable for the work presented in the manuscript.